Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

490 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. Sandborn WJ, et al. Among authors: panes j. Aliment Pharmacol Ther. 2022 Feb;55(4):464-478. doi: 10.1111/apt.16712. Epub 2021 Dec 1. Aliment Pharmacol Ther. 2022. PMID: 34854095 Free PMC article.
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ; PRECiSE 2 Study Investigators. Schreiber S, et al. Among authors: panes j. Am J Gastroenterol. 2010 Jul;105(7):1574-82. doi: 10.1038/ajg.2010.78. Epub 2010 Mar 16. Am J Gastroenterol. 2010. PMID: 20234346 Clinical Trial.
The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA, Sandborn WJ, Travis SP, Colombel JF. Van Assche G, et al. Among authors: panes j. Am J Gastroenterol. 2011 Sep;106(9):1594-602; quiz 1593, 1603. doi: 10.1038/ajg.2011.211. Epub 2011 Aug 16. Am J Gastroenterol. 2011. PMID: 21844919 Review.
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W; Study A3921063 Investigators. Sandborn WJ, et al. Among authors: panes j. N Engl J Med. 2012 Aug 16;367(7):616-24. doi: 10.1056/NEJMoa1112168. N Engl J Med. 2012. PMID: 22894574 Free article. Clinical Trial.
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.
García-Bosch O, Gisbert JP, Cañas-Ventura A, Merino O, Cabriada JL, García-Sánchez V, Gutiérrez A, Nos P, Peñalva M, Hinojosa J, García-Planella E, Muñoz F, Calvet X, Panés J. García-Bosch O, et al. Among authors: panes j. J Crohns Colitis. 2013 Oct;7(9):717-22. doi: 10.1016/j.crohns.2012.10.004. Epub 2012 Nov 8. J Crohns Colitis. 2013. PMID: 23142005
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P. Vermeire S, et al. Among authors: panes j. Lancet. 2014 Jul 26;384(9940):309-18. doi: 10.1016/S0140-6736(14)60661-9. Epub 2014 May 9. Lancet. 2014. PMID: 24814090 Free article. Clinical Trial.
490 results